141 related articles for article (PubMed ID: 16189265)
1. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects.
Gleixner KV; Mayerhofer M; Aichberger KJ; Derdak S; Sonneck K; Böhm A; Gruze A; Samorapoompichit P; Manley PW; Fabbro D; Pickl WF; Sillaber C; Valent P
Blood; 2006 Jan; 107(2):752-9. PubMed ID: 16189265
[TBL] [Abstract][Full Text] [Related]
2. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.
Gotlib J; Berubé C; Growney JD; Chen CC; George TI; Williams C; Kajiguchi T; Ruan J; Lilleberg SL; Durocher JA; Lichy JH; Wang Y; Cohen PS; Arber DA; Heinrich MC; Neckers L; Galli SJ; Gilliland DG; Coutré SE
Blood; 2005 Oct; 106(8):2865-70. PubMed ID: 15972446
[TBL] [Abstract][Full Text] [Related]
3. PI3 kinase is indispensable for oncogenic transformation by the V560D mutant of c-Kit in a kinase-independent manner.
Lindblad O; Kazi JU; Rönnstrand L; Sun J
Cell Mol Life Sci; 2015 Nov; 72(22):4399-407. PubMed ID: 26040420
[TBL] [Abstract][Full Text] [Related]
4. Midostaurin: a magic bullet that blocks mast cell expansion and activation.
Valent P; Akin C; Hartmann K; George TI; Sotlar K; Peter B; Gleixner KV; Blatt K; Sperr WR; Manley PW; Hermine O; Kluin-Nelemans HC; Arock M; Horny HP; Reiter A; Gotlib J
Ann Oncol; 2017 Oct; 28(10):2367-2376. PubMed ID: 28945834
[TBL] [Abstract][Full Text] [Related]
5. Poor Applicability of Currently Available Prognostic Scoring Systems for Prediction of Outcome in
Naumann N; Rudelius M; Lübke J; Christen D; Bresser J; Sotlar K; Metzgeroth G; Fabarius A; Hofmann WK; Panse J; Horny HP; Cross NCP; Reiter A; Schwaab J
Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339343
[TBL] [Abstract][Full Text] [Related]
6. Pharmaco-phosphoproteomic analysis of cancer-associated KIT mutations D816V and V560G.
Murray HC; Miller K; Dun MD; Verrills NM
Proteomics; 2024 May; 24(9):e2300309. PubMed ID: 38334196
[TBL] [Abstract][Full Text] [Related]
7. Chronic mast cell leukemia: a novel leukemia-variant with distinct morphological and clinical features.
Valent P; Sotlar K; Sperr WR; Reiter A; Arock M; Horny HP
Leuk Res; 2015 Jan; 39(1):1-5. PubMed ID: 25443885
[TBL] [Abstract][Full Text] [Related]
8. SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted.
Mancini M; Monaldi C; De Santis S; Papayannidis C; Rondoni M; Sartor C; Bruno S; Pagano L; Criscuolo M; Zanotti R; Bonifacio M; Tosi P; Arock M; Valent P; Cavo M; Soverini S
Biomark Res; 2023 Mar; 11(1):29. PubMed ID: 36894973
[TBL] [Abstract][Full Text] [Related]
9. Mast cell leukaemia progressed from myelodysplastic syndrome after acquiring KIT mutation.
Xu K; Childerhouse A; Gupta R
Int J Lab Hematol; 2024 Apr; 46(2):212-213. PubMed ID: 37723128
[No Abstract] [Full Text] [Related]
10. Ultrastructural, cytogenetic, and molecular findings in mast cell leukemia: Case report.
Bosch-Vilaseca A; Monter-Rovira A; Cisa-Wieczorek S; Oñate G; Bussaglia E; Carricondo M; Remacha Á; Martínez C; Pratcorona M; Blanco ML; Nomdedéu JF
Clin Case Rep; 2019 Jul; 7(7):1395-1398. PubMed ID: 31360496
[TBL] [Abstract][Full Text] [Related]
11. Dasatinib overrides the differentiation blockage in a patient with mutant-
Kampa-Schittenhelm KM; Vogel W; Bonzheim I; Fend F; Horger M; Kanz L; Soekler M; Schittenhelm MM
Oncotarget; 2018 Feb; 9(14):11876-11882. PubMed ID: 29545943
[TBL] [Abstract][Full Text] [Related]
12. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts.
Valent P; Akin C; Metcalfe DD
Blood; 2017 Mar; 129(11):1420-1427. PubMed ID: 28031180
[TBL] [Abstract][Full Text] [Related]
13. Coronavirus Receptor Expression Profiles in Human Mast Cells, Basophils, and Eosinophils.
Degenfeld-Schonburg L; Sadovnik I; Smiljkovic D; Peter B; Stefanzl G; Gstoettner C; Jaksch P; Hoetzenecker K; Aigner C; Radtke C; Arock M; Sperr WR; Valent P
Cells; 2024 Jan; 13(2):. PubMed ID: 38247864
[TBL] [Abstract][Full Text] [Related]
14. Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts.
Valent P; Akin C; Arock M; Gleixner KV; Greinix H; Hermine O; Horny HP; Ivanov D; Orfao A; Rabitsch W; Reiter A; Schulenburg A; Sotlar K; Sperr WR; Ustun C
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894806
[TBL] [Abstract][Full Text] [Related]
15. Antineoplastic efficacy profiles of avapritinib and nintedanib in
Degenfeld-Schonburg L; Gamperl S; Stefanzl G; Schruef AK; Sadovnik I; Bauer K; Smiljkovic D; Eisenwort G; Peter B; Greiner G; Hadzijusufovic E; Schwaab J; Sperr WR; Hoermann G; Kopanja S; Szépfalusi Z; Hoetzenecker K; Jaksch P; Reiter A; Arock M; Valent P
Am J Cancer Res; 2023; 13(2):355-378. PubMed ID: 36895976
[TBL] [Abstract][Full Text] [Related]
16. Clearance of bone marrow mast cells after hypomethylating agent and venetoclax for systemic mastocytosis associated with myeloid neoplasia.
Pourhassan H; Kim Y; Pullarkat V
Eur J Haematol; 2023 Feb; 110(2):213-216. PubMed ID: 36335580
[TBL] [Abstract][Full Text] [Related]
17. Assessing the Activation of Tyrosine Kinase KIT through Free Energy Calculations.
Sandoval-Pérez A; Winger BA; Jacobson MP
J Chem Theory Comput; 2022 Oct; 18(10):6251-6258. PubMed ID: 36166736
[TBL] [Abstract][Full Text] [Related]
18. Clinical challenge for gastroenterologists-Gastrointestinal manifestations of systemic mastocytosis: A comprehensive review.
Elvevi A; Elli EM; Lucà M; Scaravaglio M; Pagni F; Ceola S; Ratti L; Invernizzi P; Massironi S
World J Gastroenterol; 2022 Aug; 28(29):3767-3779. PubMed ID: 36157547
[TBL] [Abstract][Full Text] [Related]
19. Systemic Mastocytosis and Other Entities Involving Mast Cells: A Practical Review and Update.
El Hussein S; Chifotides HT; Khoury JD; Verstovsek S; Thakral B
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884535
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
